135 related articles for article (PubMed ID: 38677148)
21. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
[TBL] [Abstract][Full Text] [Related]
22. Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps.
Kilty SJ; Lasso A
J Otolaryngol Head Neck Surg; 2022 Apr; 51(1):17. PubMed ID: 35468866
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
24. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.
Galletti C; Ragusa M; Sireci F; Ciodaro F; Barbieri MA; Giunta G; Grigaliute E; Immordino A; Lorusso F; Dispenza F; Freni F; Galletti F; Gallina S; La Mantia I; Galletti B
Am J Otolaryngol; 2024; 45(1):104106. PubMed ID: 37948824
[TBL] [Abstract][Full Text] [Related]
25. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.
Rosso C; De Corso E; Conti V; Nitro L; Saibene AM; Parazzini E; Rinaldo R; De Pascalis S; Arnone F; Centanni S; Montuori C; D'Auria LM; Felisati G; Pipolo C
Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3017-3023. PubMed ID: 38347197
[TBL] [Abstract][Full Text] [Related]
26. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
[TBL] [Abstract][Full Text] [Related]
28. Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.
Nitro L; Bulfamante AM; Rosso C; Saibene AM; Arnone F; Felisati G; Pipolo C
Acta Otorhinolaryngol Ital; 2022 Jun; 42(3):199-204. PubMed ID: 35880360
[TBL] [Abstract][Full Text] [Related]
29. Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.
Boyle JV; Lam K; Han JK
Immunotherapy; 2020 Feb; 12(2):111-121. PubMed ID: 32075470
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
31. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
32. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
[TBL] [Abstract][Full Text] [Related]
33. Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP).
Garvey E; Naimi B; Duffy A; Hannikainen P; Kahn C; Farquhar D; Rosen M; Rabinowitz M; Toskala E; Nyquist G
Int Forum Allergy Rhinol; 2024 Mar; 14(3):651-659. PubMed ID: 37506043
[TBL] [Abstract][Full Text] [Related]
34. Economic Evaluation of Dupilumab Versus Endoscopic Sinus Surgery for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.
Parasher AK; Gliksman M; Segarra D; Lin T; Rudmik L; Quast T
Int Forum Allergy Rhinol; 2022 Jun; 12(6):813-820. PubMed ID: 34874120
[TBL] [Abstract][Full Text] [Related]
35. The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP).
Hardison SA; Senior BA
J Otolaryngol Head Neck Surg; 2023 Sep; 52(1):64. PubMed ID: 37759322
[TBL] [Abstract][Full Text] [Related]
36. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
Lee SE; Hopkins C; Mullol J; Msihid J; Guillemin I; Amin N; Mannent LP; Li Y; Siddiqui S; Chuang CC; Kamat S; Khan AH
Allergy; 2022 Jul; 77(7):2211-2221. PubMed ID: 35034364
[TBL] [Abstract][Full Text] [Related]
37. Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis.
Brkic FF; Liu DT; Rücklinger I; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Gangl K; Schneider S
J Otolaryngol Head Neck Surg; 2023 Nov; 52(1):75. PubMed ID: 38007429
[TBL] [Abstract][Full Text] [Related]
38. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.
van der Lans RJL; Otten JJ; Adriaensen GFJPM; Hoven DR; Benoist LB; Fokkens WJ; Reitsma S
Allergy; 2023 Oct; 78(10):2684-2697. PubMed ID: 37394895
[TBL] [Abstract][Full Text] [Related]
39. Dupilumab's impact on nasal citology: Real life experience after 1 year of treatment.
Gelardi M; Giancaspro R; Quaranta VN; La Gatta E; Ruzza A; Cassano M
Am J Otolaryngol; 2024; 45(4):104275. PubMed ID: 38574514
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care.
Galletti C; Ciodaro F; Barbieri MA; Gambino F; Ferrisi MG; Portelli D; Catalano N; Spina E; Freni F; Galletti B
Am J Otolaryngol; 2024; 45(4):104329. PubMed ID: 38696895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
